New Market Report: Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H2 2013

From: Fast Market Research, Inc.
Published: Wed Sep 04 2013


Global Markets Direct's, 'Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections. Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Full Report Details at
- http://www.fastmr.com/prod/666841_vancomycinresistant_enterococcus_faecium.aspx?afid=303

Scope

* A snapshot of the global therapeutic scenario for Vancomycin-Resistant Enterococcus Faecium Infections.
* A review of the Vancomycin-Resistant Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Vancomycin-Resistant Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Vancomycin-Resistant Enterococcus Faecium Infections.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Enterococcus Faecium Infections - Pipeline Review, H2 2012
- Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2013
- Enterococcus Infections - Pipeline Review, H1 2013
- Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2013
- Fungal Infections - Pipeline Review, H2 2013

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »